TNFα Is an Effective Therapeutic Target for Rheumatoid Arthritisa
- 1 September 1995
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 766 (1) , 272-278
- https://doi.org/10.1111/j.1749-6632.1995.tb26675.x
Abstract
Click on the article title to read more.Keywords
This publication has 17 references indexed in Scilit:
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritisArthritis & Rheumatism, 1993
- How important are t cells in chronic rheumatoid synovitis?Arthritis & Rheumatism, 1990
- INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITISThe Lancet, 1989
- Cytokine production in culture by cells isolated from the synovial membraneJournal of Autoimmunity, 1989
- Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritisEuropean Journal of Immunology, 1988
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987
- An interleukin 1 like factor stimulates bone resorption in vitroNature, 1983